The European League Against Rheumatism (EULAR) has issued provisional treatment recommendations for patients with rheumatic and musculoskeletal disease (RMD) who have contracted or tested positive for SARS-CoV-2, the virus causing COVID-19.
The recommendations, presented at the recent virtual EULAR annual meeting and published simultaneously in the Annals of the Rheumatic Diseases (2020;0:1-8), endorse continuing medications and vaccination.